The next phase of progress in MF will depend on better predictive biomarkers, more standardized use of genomic data

The gap

Evidence profile

Sourced from the future work of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 3 journals. Those papers have been cited 40 times in total.

Supporting evidence — 3 representative gaps

• SAFETY OF SYSTEMIC JAK INHIBITORS IN DERMATOLOGIC DISEASES: A SYSTEMATIC REVIEW (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi

  The future of systemic JAK inhibitor therapy in dermatology will be associated with further development in terms of selectivity, safety profile, and personalized therapy approaches. Even though the existing drugs are quite effective in inflammatory or autoimmune skin diseases, the risks associated with infections, cardiovascular diseases, blood clots, and cancer require the implementation of new strategies for safe treatment. The current efforts in this field are focused on the creation of new selective JAK inhibitors, which will target only some pathways and minimize off-target immunosuppression. A major breakthrough in this area is related to the emergence of selective TYK2 inhibitors like Deucravacitinib.[29] Further developments in precision medicine and pharmacogenomics will also be important for shaping the future application of systemic JAK inhibitors in dermatology. The discovery of predictive biomarkers can assist doctors in identifying those patients who stand to gain from treatment without incurring undue risks of adverse reactions. Tailored approaches to www.wjpps.com │ Vol 15, Issue 7, 2026. │ ISO 9001:2015 Certified Journal │ 226 Dheenadhaylan et al. World Journal of Pharmacy and Pharmaceutical Sciences treatment according to patients’ genetic predispositions, cytokine profiles, immunological characteristics, and condition severity may enhance the effectiveness of the drugs used and avoid unnecessary use of immunosuppressants. Artificial intelligence and machine learning systems can aid in predicting the outcome of treatment and potential side effects and contribute to evidence-based decision-making. In addition, future studies will focus on collecting long-term data on real-world safety, comparative efficacy analysis, and optimization of combined regimens. The implementation of comprehensive post-marketing surveillance schemes as well as patient registers internationally is required to gain more information on the risks related to long-term exposure to JAK inhibitors in relation to developing cancer and cardiovascular side effects. A possible improvement of therapy that can be achieved through the combination of JAK inhibitors with biologics, phototherapy, or topicals will provide an opportunity for increasing efficacy without the need to administer higher doses. It should also be noted that clinical trials among children, older patients, and those with various comorbid conditions will facilitate more informed dosing recommendations.[30] CONCLUSION Janus kinase inhibitors (JAK) have been introduced as an effective treatment modality for patients with several inflammatory and autoimmune dermatologic disorders. By virtue of their

  generalfuture work
  Keywords: inhibitors treatment patients future therapy risks systemic dermatology associated further safety approaches drugs effective inflammatory
• Precision medicine in myelofibrosis: from molecular profiling to personalized therapy (2026) · Frontiers in Oncology · doi

  The next phase of progress in MF will depend on better predictive biomarkers, more standardized use of genomic data, earlier identification of biologically aggressive disease, and more deliberate integration of clinical-trial strategies into routine care. Combination therapy and biologically matched approaches may further shift practice away from symptom control alone, but their value will still depend on whether they improve meaningful clinical outcomes in clearly defined patient subsets (6, 13, 19). Equally important is the refinement of selection frameworks that help clinicians decide when a JAK inhibitor is sufficient, when it

  generalfuture work
  Keywords: depend biologically clinical next phase progress better predictive biomarkers standardized genomic earlier identi cation aggressive
• The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives (2024) · International Journal of Molecular Sciences · cited 40× · doi

  Undoubtedly, the future of PG treatment lies in targeted therapies. Ongoing research on the pathogenesis of the disease and emerging insights into the pathomechanisms provide hope for the integration of both existing and novel molecules in the treatment paradigm. 4.1. Janus Kinase Inhibitors (JAKi) As in many other dermatological conditions, Janus Kinase inhibitors (JAKi) may be the future of the treatment of PG. Tofacitinib is an oral JAK-1 and JAK-3 inhibitor that has been approved for the treatment of rheumatoid arthritis and ulcerative colitis, plaque psoriasis, atopic dermatitis, vitiligo, and alopecia areata. Cases are reporting successful resolution of PG ulcers in patients treated with JAKi due to concomitant medical conditions. Other JAKi including tofacitinib, baricitinib, upadacitinib, and ruxolitinib were reported as effective treatment options [168–171]. We present available case reports in Table 9. Currently, there is an ongoing phase 2 open-label, proof-of-concept, study of baricitinib for the treatment of pyoderma gangrenosum [172] (Table 10). Int. J. Mol. Sci. 2024, 25, 2440 17 of 25 Table 9. A summary of clinical studies concerning Janus Kinase inhibitors.

  generalfuture work
  Keywords: treatment jaki janus kinase inhibitors future ongoing conditions tofacitinib baricitinib undoubtedly lies targeted therapies pathogenesis

Questions about this gap